サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1446523

米国の動物用医薬品市場規模、シェア、動向分析レポート：製品タイプ別、動物タイプ別、投与経路別、流通チャネル別、セグメント別予測、2024年～2030年

U.S. Veterinary Medicine Market Size, Share & Trends Analysis Report By Product (Biologics, Pharmaceuticals), By Animal Type, By Route Of Administration, By Distribution Channel, And Segment Forecasts, 2024 - 2030
出版日: | 発行: Grand View Research | ページ情報: 英文 70 Pages | 納期: 2～10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
米国の動物用医薬品市場規模、シェア、動向分析レポート：製品タイプ別、動物タイプ別、投与経路別、流通チャネル別、セグメント別予測、2024年～2030年
出版日: 2024年02月19日
発行: Grand View Research
ページ情報: 英文 70 Pages
納期: 2～10営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

米国の動物用医薬品市場の成長と動向：

Grand View Research, Inc.の最新レポートによると、米国の動物用医薬品市場規模は2030年までに218億米ドルに達すると予測され、2024年から2030年までのCAGRは6.8%で成長すると予測されています。

人畜共通感染症の罹患率の上昇、家畜人口の増加、予防医療への注目の高まり、ペット医療の進歩、ペット所有率の増加が市場成長の主な要因です。米国ペット用品協会（APPA）が2023年3月に発表した報告書によると、米国で最も人気のあるペットは犬で、6,510万世帯が犬を飼っています。2位は猫で4,650万世帯、3位は淡水魚で1,110万世帯となっています。

家畜の数が大幅に増加したため、人獣共通感染症や慢性疾患が増加しています。このため、家畜の健康と生産性を維持するための予防医療対策が重視されるようになっています。さらに、技術の進歩は、診断能力、治療オプション、医療機器を強化することで獣医学に革命をもたらし、動物ケアの質を向上させています。

米国の動物用医薬品市場レポート・ハイライト

  • 製品別では、研究開発への投資拡大と医療分野の進歩により、医薬品分野が2023年に67.6%の最大収益シェアで市場をリードしました。
  • 動物タイプ別では、人口増加と畜産業の世界化による動物性タンパク質需要の増加により、生産動物セグメントが2023年に58.5%の最大収益シェアで市場を占めました。コンパニオンアニマルは、予測期間中に最も速いCAGRを示すと予測されています。
  • 投与経路別では、2023年には注射剤が市場を席巻し、ペットの飼育増加と予防ヘルスケアへの注力により、経口剤が予測期間中にCAGRで大幅な伸びを示すと予測されます。
  • 流通チャネル別では、動物病院・クリニックセグメントが2023年の市場シェアの大半を占め、eコマースセグメントが予測期間で最も速いCAGRで成長すると予測されています。
  • 2024年2月、Merck &Co., Inc.は、水生動物用の医薬品とワクチン、フード、サプリメントの革新的なポートフォリオを含むElancoの水生動物事業を買収する最終契約の締結を発表しました。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 米国の動物用医薬品市場の変数、動向、範囲

  • 市場系統の見通し
    • 親市場の見通し
    • 関連/付随市場の見通し
  • 市場力学
    • 市場促進要因分析
    • 市場抑制要因分析
  • 米国の動物用医薬品市場分析ツール
    • 業界分析- ポーターのファイブフォース分析
    • PESTEL分析

第4章 米国の動物用医薬品市場：製品推定・動向分析

  • 製品市場シェア、2023年と2030年
  • セグメントダッシュボード
  • 製品別の米国動物用医薬品市場の見通し
  • 市場規模、予測および動向分析、2018年から2030年まで

第5章 米国の動物用医薬品市場：動物の種類の推定・動向分析

  • 動物タイプの市場シェア、2023年と2030年
  • セグメントダッシュボード
  • 米国の動物用医薬品市場の動物タイプ別の見通し
  • 市場規模、予測および動向分析、2018年から2030年まで

第6章 米国の動物用医薬品市場：投与経路の推定・動向分析

  • 投与経路の市場シェア、2023年と2030年
  • セグメントダッシュボード
  • 投与経路別の米国動物用医薬品市場の見通し
  • 市場規模、予測および動向分析、2018年から2030年まで

第7章 米国の動物用医薬品市場：流通チャネルの推定・動向分析

  • 流通チャネル市場シェア、2023年と2030年
  • セグメントダッシュボード
  • 流通別の米国動物用医薬品市場の見通し
  • 市場規模、予測および動向分析、2018年から2030年まで

第8章 競合情勢

  • 主要市場参入企業による最近の動向と影響分析
  • 会社/競合の分類
  • ベンダー情勢
    • List of key distributors and channel partners
    • Key customers
    • Key company market heat map analysis, 2023
  • 企業プロファイル
    • Zoetis Services LLC
    • Boehringer Ingelheim International GmbH
    • Merck &Co., Inc.
    • Elanco
    • Ceva
    • Phibro Animal Health Corporation
    • Bimeda Corporate
    • IDEXX
    • Vetbiologics
    • Neogen Corporation
    • ADM
    • Kindred Biosciences, Inc.
    • Cargill, Incorporated
図表

List of Tables

  • Table 1 List of abbreviations
  • Table 2 U.S. veterinary medicine market, by product, 2018 - 2030 (USD Million)
  • Table 3 U.S. veterinary medicine market, by animal type, 2018 - 2030 (USD Million)
  • Table 4 U.S. veterinary medicine market, by route of administration, 2018 - 2030 (USD Million)
  • Table 5 U.S. veterinary medicine market, by distribution channel, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Primary interviews in North America
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 QFD modeling for market share assessment
  • Fig. 8 Market formulation & validation
  • Fig. 9 U.S. Veterinary medicine market: market outlook
  • Fig. 10 U.S. Veterinary medicine competitive insights
  • Fig. 11 Parent market outlook
  • Fig. 12 Related/ancillary market outlook
  • Fig. 13 Penetration and growth prospect mapping
  • Fig. 14 Industry value chain analysis
  • Fig. 15 U.S. Veterinary medicine market driver impact
  • Fig. 16 U.S. Veterinary medicine market restraint impact
  • Fig. 17 U.S. Veterinary medicine market strategic initiatives analysis
  • Fig. 18 U.S. Veterinary medicine market: Product outlook and key takeaways
  • Fig. 19 Biologics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 20 Vaccines market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 21 Modified/ Attenuated live market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 22 Inactivated (Killed) market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 23 Other vaccines market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 24 Other biologics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 25 Pharmaceuticals market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 26 Parasiticides market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 27 Anti-infectives market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 28 Anti-inflammatory market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 29 Analgesics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 30 Others market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 31 Medicated feed additives market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 32 U.S. Veterinary medicine market: Animal type movement analysis
  • Fig. 33 U.S. Veterinary medicine market: Animal type outlook and key takeaways
  • Fig. 34 Production animals market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 35 Poultry market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 36 Pigs market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 37 Cattle market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 38 Sheep & goats market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 39 Others market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 40 Companion animals market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 41 Dogs market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 42 Cats market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 43 Horses market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 44 Others market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 45 U.S. Veterinary medicine Market: Product movement Analysis
  • Fig. 46 U.S. Veterinary medicine market: Route of administration movement analysis
  • Fig. 47 U.S. Veterinary medicine market: Route of administration outlook and key takeaways
  • Fig. 48 Oral market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 49 Injectable market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 50 Topical market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 51 Other routes market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 52 U.S. Veterinary medicine market: Distribution channel movement analysis
  • Fig. 53 U.S. Veterinary medicine market: Distribution channel outlook and key takeaways
  • Fig. 54 U.S. Veterinary hospitals & clinics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 55 E-commerce market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 56 Offline retail stores market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 57 Others market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 58 Market share of key market players- U.S. Veterinary medicine market
目次
Product Code: GVR-4-68040-197-8

U.S. Veterinary Market Growth & Trends:

The U.S. veterinary medicine market size is anticipated to reach USD 21.80 billion by 2030 and is projected to grow at a CAGR of 6.8% from 2024 to 2030, according to a new report by Grand View Research, Inc. The rising incidence rates of zoonotic diseases, increased livestock population, growing focus on preventive care, advancements in pet medicine and increasing pet ownership are the major factors contributing to the market growth. According to the March 2023 report released by the American Pet Products Association (APPA), dogs are the most popular pets in the U.S., with 65.1 million households owning a dog. Cats come in second with 46.5 million households, followed by freshwater fish with 11.1 million households.

The livestock population has grown significantly, leading to an increase in zoonotic diseases and chronic diseases. This has led to a growing emphasis on preventive healthcare measures to maintain the health and productivity of animals. Moreover, advancements in technology have revolutionized veterinary medicine by enhancing diagnostic capabilities, treatment options, and medical devices, thereby improving the quality of animal care.

U.S. Veterinary Medicine Market Report Highlights:

  • Based on products, the pharmaceuticals segment led the market with the largest revenue share of 67.6% in 2023, owing to growing investments in research and development and advancements in the field of medicine
  • Based on the animal type, the production animals segment held the market with largest revenue share of 58.5% in 2023, due to an increasing demand for animal protein due to population growth and globalization of livestock production. Companion animals in animal type segment are anticipated to witness fastest CAGR over the forecast period
  • Based on route of administration, the injectable segment dominated the market in 2023 and oral segment is anticipated to witness a significant growth in CAGR over the forecast period, owing to an increasing pet ownership and focus on preventive healthcare
  • Based on distribution channel, the veterinary hospitals & clinics segment held the majority of the market share in 2023 and e-commerce segment is expected to grow at the fastest CAGR over forecast period
  • In February 2024, Merck & Co., Inc. announced the signing of a definitive agreement to acquire the aqua business of Elanco, which includes an innovative portfolio of medications and vaccines, food, and supplements for aquatic animals

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Product
    • 1.2.2. Animal type
    • 1.2.3. Route of administration
    • 1.2.4. Distribution channel
    • 1.2.5. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
      • 1.4.5.1. Data for primary interviews in North America
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Volume price analysis (Model 2)
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Product outlook
    • 2.2.2. Animal type outlook
    • 2.2.3. Route of administration outlook
    • 2.2.4. Distribution channel outlook
  • 2.3. Competitive Insights

Chapter 3. U.S. Veterinary Medicine Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Increasing pet ownership
      • 3.2.1.2. Rising incidences of zoonotic diseases
      • 3.2.1.3. Advancements in pet medicine
      • 3.2.1.4. Growing focus on preventive care.
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. Stringent regulations & approvals
      • 3.2.2.2. Rising costs associated with animal healthcare
  • 3.3. U.S. Veterinary Medicine Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape
      • 3.3.2.4. Social landscape
      • 3.3.2.5. Legal landscape
      • 3.3.2.6. Environmental landscape

Chapter 4. U.S. Veterinary Medicine Market: Product Estimates & Trend Analysis

  • 4.1. Product Market Share, 2023 & 2030
  • 4.2. Segment Dashboard
  • 4.3. U.S. Veterinary Medicine Market by Product Outlook
  • 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 4.4.1. Biologics
      • 4.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.1.1.1. Vaccines
      • 4.4.1.1.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.1.1.1.1.1. Modified/ Attenuated live
      • 4.4.1.1.1.1.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.1.1.1.1.2. Inactivated (Killed)
      • 4.4.1.1.1.1.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.1.1.1.1.3. Other vaccines
      • 4.4.1.1.1.1.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.1.1.2. Other biologics
      • 4.4.1.1.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.2. Pharmaceuticals
      • 4.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.2.1.1. Parasiticides
      • 4.4.2.1.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.2.1.2. Anti-infectives
      • 4.4.2.1.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.2.1.3. Anti-inflammatory
      • 4.4.2.1.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.2.1.4. Analgesics
      • 4.4.2.1.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.2.1.5. Others
    • 4.4.3. Medicated feed additives
      • 4.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. U.S. Veterinary Medicine Market: Animal Type Estimates & Trend Analysis

  • 5.1. Animal Type Market Share, 2023 & 2030
  • 5.2. Segment Dashboard
  • 5.3. U.S. Veterinary Medicine Market by Animal Type Outlook
  • 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 5.4.1. Production animals
      • 5.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 5.4.1.1.1. Poultry
      • 5.4.1.1.1.1. Market estimated and forecasts 2018 to 2030 (USD Million)
      • 5.4.1.1.2. Pigs
      • 5.4.1.1.2.1. Market estimated and forecasts 2018 to 2030 (USD Million)
      • 5.4.1.1.3. Cattle
      • 5.4.1.1.3.1. Market estimated and forecasts 2018 to 2030 (USD Million)
      • 5.4.1.1.4. Sheep & goats
      • 5.4.1.1.4.1. Market estimated and forecasts 2018 to 2030 (USD Million)
      • 5.4.1.1.5. Others
      • 5.4.1.1.5.1. Market estimated and forecasts 2018 to 2030 (USD Million)
    • 5.4.2. Companion animals
      • 5.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 5.4.2.1.1. Dogs
      • 5.4.2.1.1.1. Market estimated and forecasts 2018 to 2030 (USD Million)
      • 5.4.2.1.2. Cats
      • 5.4.2.1.2.1. Market estimated and forecasts 2018 to 2030 (USD Million)
      • 5.4.2.1.3. Horses
      • 5.4.2.1.3.1. Market estimated and forecasts 2018 to 2030 (USD Million)
      • 5.4.2.1.4. Others
      • 5.4.2.1.4.1. Market estimated and forecasts 2018 to 2030 (USD Million)

Chapter 6. U.S. Veterinary Medicine Market: Route of Administration Estimates & Trend Analysis

  • 6.1. Route of administration Market Share, 2023 & 2030
  • 6.2. Segment Dashboard
  • 6.3. U.S. Veterinary Medicine Market by Route of Administration Outlook
  • 6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 6.4.1. Oral
      • 6.4.1.1. Market estimates and forecasts 2018 to 2030 (USD million)
    • 6.4.2. Injectable
      • 6.4.2.1. Market estimates and forecasts 2018 to 2030 (USD million)
    • 6.4.3. Topical
      • 6.4.3.1. Market estimates and forecasts 2018 to 2030 (USD million)
    • 6.4.4. Other routes
      • 6.4.4.1. Market estimates and forecasts 2018 to 2030 (USD million)

Chapter 7. U.S. Veterinary Medicine Market: Distribution Channel Estimates & Trend Analysis

  • 7.1. Distribution Channel Market Share, 2023 & 2030
  • 7.2. Segment Dashboard
  • 7.3. U.S. Veterinary Medicine Market by Distribution Outlook
  • 7.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 7.4.1. Veterinary hospitals & clinics
      • 7.4.1.1. Market estimates and forecasts 2018 to 2030 (USD million)
    • 7.4.2. E-commerce
      • 7.4.2.1. Market estimates and forecasts 2018 to 2030 (USD million)
    • 7.4.3. Offline retail stores
      • 7.4.3.1. Market estimates and forecasts 2018 to 2030 (USD million)
    • 7.4.4. Others
      • 7.4.4.1. Market estimates and forecasts 2018 to 2030 (USD million)

Chapter 8. Competitive Landscape

  • 8.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 8.2. Company/Competition Categorization
  • 8.3. Vendor Landscape
    • 8.3.1. List of key distributors and channel partners
    • 8.3.2. Key customers
    • 8.3.3. Key company market heat map analysis, 2023
  • 8.4. Company Profiles
    • 8.4.1. Zoetis Services LLC
      • 8.4.1.1. Company overview
      • 8.4.1.2. Financial performance
      • 8.4.1.3. Product benchmarking
      • 8.4.1.4. Strategic initiatives
    • 8.4.2. Boehringer Ingelheim International GmbH
      • 8.4.2.1. Company overview
      • 8.4.2.2. Financial performance
      • 8.4.2.3. Product benchmarking
      • 8.4.2.4. Strategic initiatives
    • 8.4.3. Merck & Co., Inc.
      • 8.4.3.1. Company overview
      • 8.4.3.2. Financial performance
      • 8.4.3.3. Product benchmarking
      • 8.4.3.4. Strategic initiatives
    • 8.4.4. Elanco
      • 8.4.4.1. Company overview
      • 8.4.4.2. Financial performance
      • 8.4.4.3. Product benchmarking
      • 8.4.4.4. Strategic initiatives
    • 8.4.5. Ceva
      • 8.4.5.1. Company overview
      • 8.4.5.2. Financial performance
      • 8.4.5.3. Product benchmarking
      • 8.4.5.4. Strategic initiatives
    • 8.4.6. Phibro Animal Health Corporation
      • 8.4.6.1. Company overview
      • 8.4.6.2. Financial performance
      • 8.4.6.3. Product benchmarking
      • 8.4.6.4. Strategic initiatives
    • 8.4.7. Bimeda Corporate
      • 8.4.7.1. Company overview
      • 8.4.7.2. Financial performance
      • 8.4.7.3. Product benchmarking
      • 8.4.7.4. Strategic initiatives
    • 8.4.8. IDEXX
      • 8.4.8.1. Company overview
      • 8.4.8.2. Financial performance
      • 8.4.8.3. Product benchmarking
      • 8.4.8.4. Strategic initiatives
    • 8.4.9. Vetbiologics
      • 8.4.9.1. Company overview
      • 8.4.9.2. Financial performance
      • 8.4.9.3. Product benchmarking
      • 8.4.9.4. Strategic initiatives
    • 8.4.10. Neogen Corporation
      • 8.4.10.1. Company overview
      • 8.4.10.2. Financial performance
      • 8.4.10.3. Product benchmarking
      • 8.4.10.4. Strategic initiatives
    • 8.4.11. ADM
      • 8.4.11.1. Company overview
      • 8.4.11.2. Financial performance
      • 8.4.11.3. Product benchmarking
      • 8.4.11.4. Strategic initiatives
    • 8.4.12. Kindred Biosciences, Inc.
      • 8.4.12.1. Company overview
      • 8.4.12.2. Financial performance
      • 8.4.12.3. Product benchmarking
      • 8.4.12.4. Strategic initiatives
    • 8.4.13. Cargill, Incorporated
      • 8.4.13.1. Company overview
      • 8.4.13.2. Financial performance
      • 8.4.13.3. Product benchmarking
      • 8.4.13.4. Strategic initiatives